Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants

INTRODUCTION: The Philippines pediatric national immunization program (NIP) included the 13-valent pneumococcal conjugate vaccine manufactured by Pfizer (PCV13-PFE) since 2015. Uptake has been slow in particular regions, with coverage only reaching all regions in 2019. Given affordability challenges...

Descripción completa

Detalles Bibliográficos
Autores principales: Perdrizet, Johnna, Horn, Emily K., Nua, Winniefer, Perez-Peralta, Judith, Nailes, Jennifer, Santos, Jaime, Ong-Lim, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482363/
https://www.ncbi.nlm.nih.gov/pubmed/34591259
http://dx.doi.org/10.1007/s40121-021-00538-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482363/
https://www.ncbi.nlm.nih.gov/pubmed/34591259
http://dx.doi.org/10.1007/s40121-021-00538-z

Ejemplares similares